文献速递血脂与心血管预防

患者心血管风险认知与他汀信念对种族他汀使用差异的影响:PALM注册研究

Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry.
PubMed 文献 · JAMA Cardiol · 2018-01-01

IMPORTANCE: African American individuals face higher atherosclerotic cardiovascular disease risk than white individuals; reasons for these differences, including potential differences in patient beliefs regarding preventive care, remain unknown.…

要点

  • 非裔患者他汀使用率及指南推荐强度用药比例均低于白人。
  • 非裔患者对他汀安全性和有效性的信任度更低,对医生信任度也更低。
  • 调整多因素后他汀治疗不足的种族差异不再显著。

核心结论

  • 非裔患者接受指南推荐他汀治疗的可能性低于白人,人口学、临床、社会经济、信念及医生因素共同解释了该差异。

研究设计与样本

  • 基于2015年PALM注册数据的回顾性分析,纳入138家美国社区诊所的5689例潜在适合他汀一级或二级预防的门诊成人,比较非裔与白人他汀使用及剂量。

临床怎么用

  • 应关注非裔患者他汀使用不足及剂量强度偏低问题,评估其对他汀安全性和有效性的信念及对医生的信任度。
  • 针对患者信念和医患信任的干预可能有助于缩小他汀治疗中的种族差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: African American individuals face higher atherosclerotic cardiovascular disease risk than white individuals; reasons for these differences, including potential differences in patient beliefs regarding preventive care, remain unknown. OBJECTIVE: To evaluate differences in statin use between white and African American patients and identify the potential causes for any observed differences. DESIGN, SETTING, AND PARTICIPANTS: Using the 2015 Patient and Provider Assessment of Lipid Management (PALM) Registry data, we compared statin use and dosing between African American and white outpatient adults who were potentially eligible for primary or secondary prevention statins. A total of 138 US community health care practices contributed to the data. Data analysis was conducted from March 2017 to May 2018. MAIN OUTCOMES AND MEASURES: Primary outcomes were use and dosing of statin therapy according to the 2013 American College of Cardiology/American Heart Association guideline by African American or white race. Secondary outcomes included lipid levels and patient-reported beliefs. Poisson regression was used to evaluate the association between race and statin undertreatment, a category combining people who were not taking a statin or those taking a dose intensity lower than recommended. RESULTS: A total of 5689 patients (806 [14.2%] African American) in the PALM registry were eligible for statin therapy. African American individuals were less likely than white individuals to be treated with a statin (570/807 [70.6%] vs 3654/4883 [74.8%]; P = .02). Among those treated, African American patients were less likely than white patients to receive a statin at guideline-recommended intensity (269 [33.3%] vs 2145 [43.9%], respectively; P < .001; relative risk, 1.07 [95% CI, 1.00-1.15]; P = .05, after adjustment for demographic and clinical factors). The median (interquartile range) low-density lipoprotein cholesterol levels of patients receiving treatment were higher among African American than white individuals (97.0 [76.0-121.0] mg/dL vs 85.0 [68.0-105.0] mg/dL; P < .001). African American individuals were less likely than white individuals to believe statins were safe (292 [36.2%] vs 2800 [57.3%]; P < .001) or effective (564 [70.0%] vs 3635 [74.4%]; P = .008) and were less likely to trust their clinician (663 [82.3%] vs 4579 [93.8%]; P < .001). Group differences in statin undertreatment were not significant after adjusting for demographic, clinical, and clinician factors, socioeconomic status, and patient beliefs (final adjusted relative risk, 1.03 [95% CI 0.96-1.11]; P = .35). CONCLUSIONS AND RELEVANCE: African American individuals were less likely to receive guideline-recommended statin therapy. Demographic, clinical, socioeconomic, belief-related, and clinician differences contributed to observed differences and represent potential targets for intervention.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Nanna MG, Navar AM, Zakroysky P, et al. Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. JAMA Cardiol. 2018. PMID: 29898219. doi:10.1001/jamacardio.2018.1511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。